EP2597086A1 - Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same - Google Patents

Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same Download PDF

Info

Publication number
EP2597086A1
EP2597086A1 EP11809933.2A EP11809933A EP2597086A1 EP 2597086 A1 EP2597086 A1 EP 2597086A1 EP 11809933 A EP11809933 A EP 11809933A EP 2597086 A1 EP2597086 A1 EP 2597086A1
Authority
EP
European Patent Office
Prior art keywords
methyl
cyclic
isomers
group
diarylthioureas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11809933.2A
Other languages
German (de)
French (fr)
Other versions
EP2597086A4 (en
Inventor
Oleg Dmitrievich Mitkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DK14001526.4T priority Critical patent/DK2767531T3/en
Priority to EP14001526.4A priority patent/EP2767531B1/en
Publication of EP2597086A1 publication Critical patent/EP2597086A1/en
Publication of EP2597086A4 publication Critical patent/EP2597086A4/en
Priority to CY20171100307T priority patent/CY1119184T1/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

  • the invention relates to novel cyclic N,N'-diarylthioureas and N,N'-diarylureas-androgen receptor antagonists, anticancer agent, pharmaceutical composition, medicament and method for treatment of cancer including prostate cancer.
  • salts prepared in this manner include hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valeriates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, p-toluenesulfonates, citrates, maleates, fumarates, succinates, tartrates, methane sulphonates, malonates, salicylates, propionates, ethane sulphonates, benzene sulfonates, sulfamates and the like (Detailed description of properties of such salts is given in: Berge S.M., et al., "Pharmaceutical Salts" J.Pharm.Sci., 1977, 66: 1-19 ).
  • Salts of disclosed acids may be also prepared by reaction of purified acids specifically with suitable base; moreover, metal salts and amine salts may be synthesized too.
  • Metal salts are salts of sodium, potassium, calcium, barium, magnesium, zink, lithium and aluminum, sodium and potassium salts being preferred.
  • Suitable inorganic bases from which metal salts can be prepared are sodium hydroxide, carbonate, bicarbonate and hydride; potassium hydroxide, carbonate and bicarbonate, lithium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide.
  • Organic bases suitable for preparation of disclosed acid salts are amines and amino acids of sufficient basicity to produce stable salt suitable for medical purposes use (in particular, they are to have low toxicity).
  • Such amines include ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, benzylamine, dibenzylamine, dicyclohexylamine, piperazine, ethylpiperidine, tris(hydroxymethyl)aminomethane and the like.
  • salts can be prepared using some tetraalkylammonium hydroxides, such as holine, tetramethylammonium, tetraethylammonium, and the like.
  • Aminoacids may be selected among main aminoacids - lysine, ornithine and agrinine.
  • the more preferable compounds are cyclic N,N'-diarylthioureas of formulas 1.2(1), 1,2(2), 1.2,2 and 1.2.3, their optical (R)-isomers - (R) -1.2(2), (R)- 1.2.2 , (R)- 1.2.3 and (S)-isomers - (S)- 1.2(2), (S)- 1.2.2 and (S)- 1.2.3 : wherein:
  • the more preferable compounds are also compounds of formulas 1.2.2(1), 1.2.2(2), 1.2.2(3), 1.2.3(1), 1.2.3(2) and 1.2.3(3), their optical (R)-isomers - (R)- 1.2.2(1), (R)-1.2.2(2), (R)-1.2.2(3), (R)- 1.2.3(1), and (S)-isomers - (S)- 1.2.2(1), (S)- 1.2.2(2), (S)- 1.2.2(3), (S)-1.2.3(1°), or a pharmaceutically acceptable salt thereof, wherein R6 represents hydroxyl group optionally substituted with methyl or benzyl,
  • the subject of the present invention is a method for preparation of compounds of the general formula 1.2 and optical (R)- and (S)- isomers thereof.
  • 1,3-Diarylhydantoines of the general formula 1.2 are prepared by interaction of isothiocyanate 3.2 with the corresponding 4-(cyanomethyl)aminobenzamides 4.1 or (4-carbamoylphenylamino) acetic acids 4.2 according to scheme 1. wherein:
  • Optically active cyclic N,N'-diarylthioureas, (R)-1.2 and (S)-1.2 isomers are prepared either from the corresponding optically active (R)-4.1, (R)-4.2, (S)-4.1 and (S)-4.2 starting materials, or by resolution of racemic mixtures of cyclic N,N'-diarylthioureas 1.2 to enantiomers.
  • 1,3-Diaryltetrahydropyrimidin-2-ones of the general formula 1.3.1 are prepared by interaction of the corresponding N,N' -diarylureas of the general formula 2 with 1,3-dibromopropane according to scheme 2. wherein:
  • 1,4-Diaryl[1,2,4]triazolidin-3,5-diones of the general formula 1.4 are prepared by interaction of the corresponding hydrazine 7 with isocyante 3.1 and subsequent condensation of the prepared semicarbazide 8 with diphosgene according to scheme 4. wherein:
  • Novel androgen receptor antagonists are also suitable for investigation of molecular mechanism of inhibition and activation of androgen receptors.
  • Novel cyclic N,N'-diarylthioureas and N,N'-diarylureas of the general formula 1 are androgen receptor antagonists, at that their activity exceeds the activity of known androgen receptor antagonists, published in patent application W02006124118 , WO2007127010 , and in Drug Data Rep., 2009, 31(6), 609 .
  • novel antagonist 1.2.2(1) is more than three times as less toxical as MDV3100 antagonist, because its maximum tolerated dose (MTD), determined in experiments with male mice of CD1 line is equel to MTD > 100 mg/kg, whilst MTD for MDV3100 is about ⁇ 30 mg/kg.
  • novel anticancer agent representing at least one cyclic N,N'-diarylthioureas or N,N'- diarylureas of the general formula 1.
  • the subject of the present invention is also novel pharmaceutical composition
  • novel pharmaceutical composition comprising as an active component at least one cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1, its optically active isomer or pharmaceutically acceptable salt exhibiting anticancer activity in effective amount.
  • the more preferable composition is the pharmaceutical composition exhibiting activity towards prostate cancer comprising as active component at least one cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1, its optical isomer or pharmaceutically acceptable salt.
  • compositions may include pharmaceutically acceptable excipients.
  • Pharmaceutically acceptable excipients mean diluents, auxiliary agents and/or carriers employing in the sphere of pharmaceutics.
  • the pharmaceutical composition in addition to the cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1, its optically active isomer or pharmaceutically acceptable salt may include other active components, among other things exhibiting anti-cancer activity, provided that they do not give rise to undesirable side-effects.
  • the pharmaceutical composition if it is necessary to use the pharmaceutical composition in clinical practice it can be mixed up with various traditional pharmaceutical carries.
  • the carriers used in pharmaceutical compositions represent carriers which are applied in the sphere of pharmaceutics for preparation of commonly used forms including: binding agents, greasing agents, disintegrators, solvents, diluents, stabilizers, suspending agents, colorless agents, taste flavors are used for peroral forms; antiseptic agents, solubilizers, stabilizers are used in the forms for injections; base materials, diluents, greasing agents, antiseptic agents are used in local forms.
  • the purpose of the present invention is also the method for preparation of pharmaceutical compositions.
  • novel anti-cancer agent with an inert exicipient and/or solvent, the distinctive feature of which consists in utilization as anticancer agent, at least, one cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1, its optically active isomer or pharmaceutically acceptable salt.
  • the subject of the present invention is also a medicament in the form of tablets, sheaths or injections including novel anticancer agent or novel pharmaceutical composition intended for cancer treatment.
  • the preferred medicament including novel anticancer agent or novel pharmaceutical composition is a medicament intended for treatment of prostate cancer.
  • the subject of the present invention is also therapeutic cocktails for treatment of cancer diseases, among them prostate cancer, includuing as one of the components novel medicament or novel pharmaceutical composition, comprising as active component at least one cyclic N,N'-diarylthiourea or N,N°-diarylurea of the general formula 1, its optically active isomer or pharmaceutically acceptable salt.
  • Therapeutic cocktails for treatment of prostate cancer, along with the medicament disclosed in the invention, may include other known drug substances intended for treatment cancer diseases.
  • the method for treatment of oncologic diseases, among them, prostate cancer, at humans and warm-blooded animals consists in introduction to human or warm-blooded animal of novel medicament, novel pharmaceutical composition or novel therapeutic cocktail.
  • Medicaments could be administered perorally or parenterally, for example, intravenously, subcutaneously, intraperitoneally or locally.
  • the clinical dosage of the active component of the general formula 1 could be corrected depending on: therapeutic efficiency and bioavailability of the active ingredients in organism, rate of their exchange and deducing from organism, and also depending on the age, sex and the severity of the patient's symptoms; the daily dosage for adults falls within the range of about 10 to about 500 mg of the active ingredient, preferably of about 50 to about 300 mg.
  • each unit of dosage should contain of about 10 to about 500 mg of the compound of the general formula 1, preferably 50 - 300 mg.
  • the above dosage can be taken several times during the definite time intervals (preferably - from one to six times).
  • N -(4-methylcarbamoyl-2-fluorophenyl)glycine 4.2(1) 113 mg, 0.5 mmol
  • 4-isothiocyanato-2-(trifluoromethyl)benzonirile 3.2 174 mg, 1.0 mmol
  • the reaction mixture was evaporated in vacuo, and N -methyl-4- ⁇ 4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-imidazolidin-1-yl ⁇ -2-fluorobenzamide 1.2(1), was isolated by HPLC method, LCMS (M+H) + 437.
  • K i 1,2(2) 140.2 nM
  • K i (S)- 1.2(2) 106.7 nM
  • K i (R)-1.2(2) 73.6 nM, respectively.
  • the reaction mixture was dissolved in MeOH (30 ml), 1N HCl (7.5 ml) was added and the resultant mixture was boiled for 1.5 h. The solution was evaporated in vacuo, treated with water, the solid was filtered off, washed with water and dried in vacuo. The product was isolated by HPLC method.
  • BBr 3 (53 mkl, 0.55 mmol) was added dropwise to solution of N -methyl-4-[5-methyl-5-(methoxymethyl)-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl]-2-fluorobenzamide (55 mg, 0.11 mmol) in CH 2 Cl 2 (1.5 ml) in argon atmosphere at -78°C. The reaction mixture was stirred at -78 °C for 3 h and then for another 3 h at room temperature.
  • Triethylamine (56 mkl, 0.4 mmol) and diphosgene (27 mkl, 0.22 mmol) were added one after another to 2-[(4-methylcarbamoyl)-3-fluorophenyl]- N -[3-(trifluoromethyl)-4-cyanophenyl]-hydrazine carboxamide (80 mg, 0.2 mmol) 8(1) in dichloroethane (2 ml).
  • the reaction mixture was stirred in a closed vial at 80 °C for 15 h.
  • the solvent was evaporated in vacuo and the residue was subjected to chromatography on SiO 2 (eluent - CH 2 Cl 2 : MeOH, gradient from 100:1 till 20:1).
  • DHT 5- ⁇ -dihydrotestosterone
  • PSA cancer markers
  • the cells were cultured in RPMI 1640 medium (Invitrogen, USA) containing 10% calf serum (Hyclone, USA), 1% antibacterial/antifungal mixture (Sigma, USA) and 4,5% glucose. Before the experiment the cells were washed and suspended in the same medium in which, however, instead of calf serum the serum which had been treated with charcoal for removal of hormone traces was used. The cells were embedded into wells of 96-well plates by 100 ⁇ l per cell (10 000 cells) and left for 4 days in incubator at 37°C (100% humidity) in atmosphere of 95% air/5% CO 2 .
  • N,N'-diarylthioureas or N,N'-diarylureas of the general formula 1 were added to the cells in various concentrations, and then - 20nM DHT (concentration corresponding to 80-90% of maximum stimulation).
  • the cells were left for 5 days for additional incubation under the same conditions.
  • the samples of supracellular medium were taken on analysis for PSA content.
  • the test was carried out according to the protocol, recommended by manufacturer of the kit for determination of PSA (Alpha Diagnostic International, USA). After wetting the wells containing PSA antibodies attached to their bottom to each well 25 ⁇ l of the tested compounds and 100 ⁇ l of PSA antibodies conjugated previously with horseradish peroxidase were added successively.
  • K i lC 50 / 1 + L / K D , wherein L - agonist concentration (DHT), K D - receptor activation constant, numerically equal to EC 50 value, which is determined in every experiment according to dependence of stimulation of PSA synthesis on DHT concentration.
  • DHT L - agonist concentration
  • K D - receptor activation constant numerically equal to EC 50 value, which is determined in every experiment according to dependence of stimulation of PSA synthesis on DHT concentration.
  • body weight of mice in the group received the tested compound in dose 100 mg/kg was less in comparison with the body weight of control animals, however, statistical significance at this was not observed ( fig.1 ).
  • the data show that compound has MTD > 100 mg/kg.
  • body weight of this group of animals statistically differed from body weight of animals from Placebo group (p 0,002, fig. 2 ).
  • N-Methyl-4-[5-methyl-5-(methoxymethyl)-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-imidazolidin-1-yl]-2-fluorobenzamide (R)-1.2.2(1) was carefully mixed with lactose powder in ratio 2 : 1.
  • the prepared pharmaceutical composition was packed on 300 mg into gelatinous capsules of suitable size.
  • the present invention could be used in medicine, veterinary, biochemistry.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to novel cyclic N,N'-diarylureas and N,N'-diarylthioureas - androgen receptor antagonists, anti-cancer agent, pharmaceutical composition, medicament, and method for treatment of cancerous diseases, among them prostate cancer.
Cyclic N,N'-diarylthioureas or N,N'-diarylureas of the general formula 1, their optical (R)- and (S)- isomers and pharmaceutically acceptable salts thereof exhibiting properties of androgen receptor antagonists have been proposed,
Figure imga0001
 wherein: X represents oxygen or sulfur;
m = 0 or 1;
R1 represents C1-C3alkyl;
R2 and R3 represent hydrogen; or
R2 and R3 together with C-atom they are attached to form C = O group; R4 and R5 represent hydrogen; or
R4 represents hydrogen, R5 represents methyl; or
R4 represents methyl, R5 represents CH2R6 group in which R6 represents C1-C3 alkoxycarbonyl, carboxyl, hydroxyl group optionally substituted with methyl or benzyl; or
R4 and R5 together with C-atom they are attached to form 5- or 6- membered heterocycle comprising at least one oxygen atom or nitrogen atom optionally substitutd with methyl; or
R4 and R5 together with C-atom they are attached to form NH group.

Description

    Field of the invention
  • The invention relates to novel cyclic N,N'-diarylthioureas and N,N'-diarylureas-androgen receptor antagonists, anticancer agent, pharmaceutical composition, medicament and method for treatment of cancer including prostate cancer.
    • Prior art
  • There are known androgen receptor antagonists which are -1,3-diaryl-5,5-dimethyl-2-thioxoimidazolidin-4-ones I, 5,7-diaryl-6-thioxo-5,7-diazaspiro[3,4]octan-8-ones II and 1,3-diaryl-2-thioxo-1,3-diazaspiro[4,4]nonan-4-ones III exhibiting anticancer activity [ WO2006124118 , WO2007127010 ]. Amongst these compounds the most promoted is 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-2-fluoro-N-methylbenzamide MDV3100 (androgen receptor antagonist with IC50= 36 nM), which is now in the III phase of clinical trials as medicament for prostate cancer treatment [Drug Data Rep., 2009, 31(6), 609].
    Figure imgb0001
  • Searching for highly effective anticancer medicaments exhibiting enhanced activity and reduced toxicity, is still one of the main directions in the development of novel pharmacological remedies for cancer treatment, including prostate cancer. In this context the development of novel anticancer active agents, pharmaceutical compositions and medicaments, and also methods for their preparation and use is of essential importance.
    • Disclosure of the invention
  • In the context of the invention, the terms are generally defined as follows:
    • "Azaheterocycle" means an aromatic or non aromatic mono- or poly- cyclic system, comprising at least one nitrogen atom in the cycle. Azaheterocycle may have one or more "cyclic system" substituents.
    • "Active component" (drug-substance) means a physiologically active compound of synthetic or other origin (biotechnological, vegetable, animal, microbe and so on), exhibiting pharmacological activity and being an active component of pharmaceutical composition, employing in production and preparation of medicaments.
    • "Alkyl" means an aliphatic hydrocarbon straight or branched chain with 1-12 carbon atoms. Branched means an alkyl chain with one or more "lower alkyl" substituents. Alkyl group may have one or more substituents of the same or different structure ("alkyl substituent") including halogen, alkenyloxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, aroyl, cyano, hydroxy, alkoxy, carboxy, alkynyloxy, aralkoxy, aryloxy, aryloxycarbonyl, alkylthio, heteroarylthio, aralkylthio, arylsulfonyl, alkylsulfonylheteroaralkyloxy and so on.
    • "Antagonists" mean ligands which being bound to definite receptors not cause active cellular responses. Antagonists prevent linkage between agonists and receptors and by that block specific receptor signal transmission.
    • "Aryl" means aromatic mono- or poly- cyclic system with 6 - 14 carbon atoms, predominantly 6-10 carbon atoms. Aryl may have one or more "cyclic system substituents" of the same or different structure. Phenyl, substituted phenyl, naphthyl, or substituted naphthyl are the representatives of aryl groups. Aryl could be annelated with nonaromatic cyclic system or heterocycle.
    • "Heterocyclyl" means aromatic or saturated mono- or polycyclic system with 3 - 10 carbon atoms, preferably from 5 to 6, wherein one or more carbon atoms are substituted by one or more heteroatoms, such as N, S or O. Prefix "aza", "oxa" or "thia" before "heterocyclyl" means that N, O or S atoms are introduced in the cycle, respectively. Heterocyclyl may have one or more "cyclic system sustituents" of the same or different structure. N- and S- atoms of heterocyclyl cycle could be oxidized to N-oxide, S-oxide or S-dioxide. Piperidinyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxane-2-yl, tetrahydrofuranyl, tetrahydrothiophenyl and others are examples of heterocyclyl.
    • "Hydrate" means stoichiometric or nonstoichiometric compositions of compounds or their salts with water.
    • "Substituent" means a chemical radical attached to scaffold (fragment), for example, "alkyl substituent", "amino group substituent", "carbamoyl substituent", and "cyclic system substituent", the meanings of which are defined in this section.
    • "Medicament" - is a compound (or mixture of compounds in the form of pharmaceutical composition) in the form of tablets, capsules, injections, ointments and other ready forms intended for restoration, improvement or modification of physiological functions at humans and animals, and also for treatment and prophylaxis of diseases, diagnostics, anesthesia, contraception, cosmetology and others.
    • "slower alkyl" means a straight or branched alkyl with 1-4 carbon atoms.
    • "Pharmaceutical composition" means a composition comprising a compound of general formula 1 and at least one of components selected from the group consisting of pharmaceutically acceptable and pharmacologicaly compatible fillers, solvents, diluents, auxiliary, distributing and sensing agents, delivery agents, such as preservatives, stabilizers, disintegrators, moisteners, emulsifiers, suspending agents, thickeners, sweeteners, flavouring agents, aromatizing agents, antibacterial agents, fungicides, lubricants, and prolonged delivery controllers, the choice and suitable proportions of which depend on the nature and way of administration and dosage. Examples of suitable suspending agents are ethoxylated isostearyl alcohol, polyoxyethene, sorbitol and sorbitol ether, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacant and their mixtures as well. Protection against the action of microorganisms can be provided by various antibacterial and antifungal agents, such as, for example, parabens, chlorobutanole, sorbic acid, and similar compounds. Composition may also contain isotonic agents, such as, for example, sugar, sodium chloride, and similar compounds. Prolonged effect of composition may be achieved by agents slowing down absorption of active ingredient, for example, aluminum monostearate and gelatine. Examples of suitable carriers, solvents, diluents and delivery agents include water, ethanol, polyalcohols and their mixtures, natural oils (such as olive oil) and organic esters (such as ethyl oleate) for injections. Examples of fillers are lactose, milk-sugar, sodium citrate, calcium carbonate, calcium phosphate and the like. Examples of disintegrators and distributors are starch, alginic acid and its salts, and silicates. Examples of suitable lubricants are magnesium stearate, sodium lauryl sulfate, talc and polyethylene glycol of high molecular weight. Pharmaceutical composition for peroral, sublingval, transdermal, intramuscular, intravenous, subcutaneous, local or rectal administration of active ingredient, alone or in combination with another active compound may be administered to humans and animals in standard administration form, or in mixture with traditional pharmaceutical carriers. Suitable standard administration forms include peroral forms such as tablets, gelatin capsules, pills, powders, granules, chewing-gums and peroral solutions or suspensions, sublingval and transbuccal administration forms; aerosols; implants; local, transdermal, subcutaneous, intramuscular, intravenous, intranasal or intraocular forms of introduction and rectal administration forms. Pharmaceutical compositions are usually prepared by means of standard procedures by mixing an active compound with liquid or overgrounded solid carrier.
    • "Pharmaceutically acceptable salt" means a relatively nontoxic both organic and inorganic salts of acids and bases disclosed in this invention. Salts could be prepared in situ in processes of synthesis, isolation or purification of compounds or be prepared specially. In particular, bases salts could be prepared starting from purified base of disclosed compound and suitable organic or mineral acid.
  • Examples of salts prepared in this manner include hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valeriates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, p-toluenesulfonates, citrates, maleates, fumarates, succinates, tartrates, methane sulphonates, malonates, salicylates, propionates, ethane sulphonates, benzene sulfonates, sulfamates and the like (Detailed description of properties of such salts is given in: Berge S.M., et al., "Pharmaceutical Salts" J.Pharm.Sci., 1977, 66: 1-19). Salts of disclosed acids may be also prepared by reaction of purified acids specifically with suitable base; moreover, metal salts and amine salts may be synthesized too. Metal salts are salts of sodium, potassium, calcium, barium, magnesium, zink, lithium and aluminum, sodium and potassium salts being preferred. Suitable inorganic bases from which metal salts can be prepared are sodium hydroxide, carbonate, bicarbonate and hydride; potassium hydroxide, carbonate and bicarbonate, lithium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide. Organic bases suitable for preparation of disclosed acid salts are amines and amino acids of sufficient basicity to produce stable salt suitable for medical purposes use (in particular, they are to have low toxicity). Such amines include ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, benzylamine, dibenzylamine, dicyclohexylamine, piperazine, ethylpiperidine, tris(hydroxymethyl)aminomethane and the like. Besides, salts can be prepared using some tetraalkylammonium hydroxides, such as holine, tetramethylammonium, tetraethylammonium, and the like. Aminoacids may be selected among main aminoacids - lysine, ornithine and agrinine. The authors have disclosed novel cyclic N,N'-diarylthioureas and N,N'-diarylureas of the general formula 1, optical (R)- and (S)- isomers and pharmaceutically acceptable salts thereof which are androgen receptor antagonists:
    Figure imgb0002
     wherein:
    • X represents oxygen or sulfur;
    • m = 0 or 1;
    • R1 represents C1-C3alkyl;
    • R2 and R3 represent hydrogen; or
    • R2 and R3 together with the C-atom they are attached to form C = O group;
    • R4 and R5 represent hydrogen; or
    • R4 represents hydrogen, R5 represents methyl; or
    • R4 represents methyl, R5 represents CH2R6 group in which R6 is C1-C3 alkoxycarbonyl; carboxyl; hydroxyl group optionally substituted with methyl or benzyl; or
    • R5 and R4 together with the C-atom they are attached to form 5- or 6- membered heterocycle comprising at least one oxygen atom or nitrogen atom optionally substituted with methyl; or
    • R4 and R5 together with the C-atom they are attached to represent NH group. The preferred compounds are N,N'-diarylthioureas and N,N'-diarylureas, their optical (R)- and (S)- isomers and pharmaceutically acceptable salts of the general formulas 1.2, 1.3 or 1.4:
    Figure imgb0003
     wherein:
    • X, R1 , R2, R3, R4 and R5 have the above meanings.
  • The more preferable compounds are cyclic N,N'-diarylthioureas of formulas 1.2(1), 1,2(2), 1.2,2 and 1.2.3, their optical (R)-isomers - (R)-1.2(2), (R)-1.2.2, (R)-1.2.3 and (S)-isomers - (S)-1.2(2), (S)-1.2.2 and (S)-1.2.3:
    Figure imgb0004
    Figure imgb0005
    Figure imgb0006
    Figure imgb0007
     wherein:
    • R5 and R4 together with the C-atom they are attached to form 5- or 6- membered heterocycle comprising at least one oxygen atom or nitrogen atom optionally substituted with methyl,
    • R6 has the meaning mentioned above.
  • The more preferable compounds are also compounds of formulas 1.2.2(1), 1.2.2(2), 1.2.2(3), 1.2.3(1), 1.2.3(2) and 1.2.3(3), their optical (R)-isomers - (R)-1.2.2(1), (R)-1.2.2(2), (R)-1.2.2(3), (R)-1.2.3(1), and (S)-isomers - (S)-1.2.2(1), (S)-1.2.2(2), (S)-1.2.2(3), (S)-1.2.3(1°), or a pharmaceutically acceptable salt thereof,
    Figure imgb0008
    Figure imgb0009
    Figure imgb0010
     wherein R6 represents hydroxyl group optionally substituted with methyl or benzyl, The subject of the present invention is a method for preparation of compounds of the general formula 1.2 and optical (R)- and (S)- isomers thereof. 1,3-Diarylhydantoines of the general formula 1.2 are prepared by interaction of isothiocyanate 3.2 with the corresponding 4-(cyanomethyl)aminobenzamides 4.1 or (4-carbamoylphenylamino) acetic acids 4.2 according to scheme 1.
    Figure imgb0011
     wherein:
    • R1, R4 and R5 have the above meanings.
    Scheme 1.
  • Optically active cyclic N,N'-diarylthioureas, (R)-1.2 and (S)-1.2 isomers, are prepared either from the corresponding optically active (R)-4.1, (R)-4.2, (S)-4.1 and (S)-4.2 starting materials, or by resolution of racemic mixtures of cyclic N,N'-diarylthioureas 1.2 to enantiomers.
    Figure imgb0012
    Figure imgb0013
    Figure imgb0014
     wherein:
    • R1, R4 and R5 have the above meanings.
  • 1,3-Diaryltetrahydropyrimidin-2-ones of the general formula 1.3.1 are prepared by interaction of the corresponding N,N'-diarylureas of the general formula 2 with 1,3-dibromopropane according to scheme 2.
    Figure imgb0015
     wherein:
    • R1 has the above meaning.
    Scheme 2.
  • Compounds of the general formula 1.3.2 are prepared by interaction of isocyanate 3.1 or isothiocyanate 3.2 with the corresponding ethyl β-alaninates of the general formula 5 with subsequent cyclization of obtained ureas of the general formula 6 according to scheme 3.
    Figure imgb0016
     wherein:
    • X and R1 have the above meanings.
    Scheme 3.
  • 1,4-Diaryl[1,2,4]triazolidin-3,5-diones of the general formula 1.4 are prepared by interaction of the corresponding hydrazine 7 with isocyante 3.1 and subsequent condensation of the prepared semicarbazide 8 with diphosgene according to scheme 4.
    Figure imgb0017
     wherein:
    • R1 has the above meaning.
    Scheme 4.
  • Novel androgen receptor antagonists are also suitable for investigation of molecular mechanism of inhibition and activation of androgen receptors.
  • Novel cyclic N,N'-diarylthioureas and N,N'-diarylureas of the general formula 1 are androgen receptor antagonists, at that their activity exceeds the activity of known androgen receptor antagonists, published in patent application W02006124118 , WO2007127010 , and in Drug Data Rep., 2009, 31(6), 609. Besides, novel antagonist 1.2.2(1) is more than three times as less toxical as MDV3100 antagonist, because its maximum tolerated dose (MTD), determined in experiments with male mice of CD1 line is equel to MTD > 100 mg/kg, whilst MTD for MDV3100 is about ~ 30 mg/kg.
  • The subject of the present invention is novel anticancer agent representing at least one cyclic N,N'-diarylthioureas or N,N'- diarylureas of the general formula 1.
  • The subject of the present invention is also novel pharmaceutical composition comprising as an active component at least one cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1, its optically active isomer or pharmaceutically acceptable salt exhibiting anticancer activity in effective amount.
  • The more preferable composition is the pharmaceutical composition exhibiting activity towards prostate cancer comprising as active component at least one cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1, its optical isomer or pharmaceutically acceptable salt.
  • Pharmaceutical compositions may include pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients mean diluents, auxiliary agents and/or carriers employing in the sphere of pharmaceutics. According to the invention the pharmaceutical composition in addition to the cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1, its optically active isomer or pharmaceutically acceptable salt may include other active components, among other things exhibiting anti-cancer activity, provided that they do not give rise to undesirable side-effects.
  • According to the present invention, if it is necessary to use the pharmaceutical composition in clinical practice it can be mixed up with various traditional pharmaceutical carries.
  • According to the present invention the carriers used in pharmaceutical compositions represent carriers which are applied in the sphere of pharmaceutics for preparation of commonly used forms including: binding agents, greasing agents, disintegrators, solvents, diluents, stabilizers, suspending agents, colorless agents, taste flavors are used for peroral forms; antiseptic agents, solubilizers, stabilizers are used in the forms for injections; base materials, diluents, greasing agents, antiseptic agents are used in local forms.
  • The purpose of the present invention is also the method for preparation of pharmaceutical compositions.
  • The object in view is achieved by mixing novel anti-cancer agent with an inert exicipient and/or solvent, the distinctive feature of which consists in utilization as anticancer agent, at least, one cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1, its optically active isomer or pharmaceutically acceptable salt. The subject of the present invention is also a medicament in the form of tablets, sheaths or injections including novel anticancer agent or novel pharmaceutical composition intended for cancer treatment.
  • The preferred medicament including novel anticancer agent or novel pharmaceutical composition is a medicament intended for treatment of prostate cancer.
  • The subject of the present invention is also therapeutic cocktails for treatment of cancer diseases, among them prostate cancer, includuing as one of the components novel medicament or novel pharmaceutical composition, comprising as active component at least one cyclic N,N'-diarylthiourea or N,N°-diarylurea of the general formula 1, its optically active isomer or pharmaceutically acceptable salt.
    Therapeutic cocktails for treatment of prostate cancer, along with the medicament disclosed in the invention, may include other known drug substances intended for treatment cancer diseases.
  • According to the present invention the method for treatment of oncologic diseases, among them, prostate cancer, at humans and warm-blooded animals consists in introduction to human or warm-blooded animal of novel medicament, novel pharmaceutical composition or novel therapeutic cocktail.
  • Medicaments could be administered perorally or parenterally, for example, intravenously, subcutaneously, intraperitoneally or locally. The clinical dosage of the active component of the general formula 1 could be corrected depending on: therapeutic efficiency and bioavailability of the active ingredients in organism, rate of their exchange and deducing from organism, and also depending on the age, sex and the severity of the patient's symptoms; the daily dosage for adults falls within the range of about 10 to about 500 mg of the active ingredient, preferably of about 50 to about 300 mg. Therefore, according to the present invention in the process of preparation of a medicament from the pharmaceutical composition as units of dosage it is necessary to keep in mind the above effective dosage, so that each unit of dosage should contain of about 10 to about 500 mg of the compound of the general formula 1, preferably 50 - 300 mg. In accordance with the recommendation of physician or pharmacist the above dosage can be taken several times during the definite time intervals (preferably - from one to six times).
    • Best Embodiment of the invention
  • The invention is illustrated by the following drawings.
    • Fig.1 . Weight change of male mice at peroral introduction of compound 1.2.2(1).
    • Fig.2 . Weight change of male mice at peroral introduction of compound MDV3100.
    The examples given below describe synthesis of N,N'-diarylthioureas and N,N'-diarylureas and data of their biological investigation, which illustrate but not limit the scope of the invention. Example 1
  • Synthesis of N-methyl-4-{4-oxo-2-thioxo-3-[3-(trifiuoromethyl)-4-cyanophenyl]imidazolidin-1-yl}-2-fluorobenzamide 1.2(1). Glycine (80 mg, 1.07 mmol) and K2CO3 (207 mg, 1.5 mmol) were added to solution of 4-iodo-N-methyl-2-fluorobenzamide (279 mg, 1 mmol) in DMF (3 ml). The reaction mixture was stirred at 140°C for 18 min. in microwave oven, cooled, diluted with AcOEt (10 ml) and water (10 ml), neutralized with HCl to pH 2-3, organic layer was separated, water layer was extracted with AcOEt (5 x 20 ml). The combined extracts were washed with brine, dried over Na2SO4 and evaporated in vacuo. The product was isolated by colomn chromatography on SiO2. It gave N-(4-methylcarbamoyl-2-fluorophenyl)glycine 4.2(1) (R1=CH3, R4=R5=H,). A solution of N-(4-methylcarbamoyl-2-fluorophenyl)glycine 4.2(1) (113 mg, 0.5 mmol) and 4-isothiocyanato-2-(trifluoromethyl)benzonirile 3.2 (174 mg, 1.0 mmol) in DMF (2 ml) was stirred at 90°C for 12 h. The reaction mixture was evaporated in vacuo, and N-methyl-4-{4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-imidazolidin-1-yl}-2-fluorobenzamide 1.2(1), was isolated by HPLC method, LCMS (M+H)+ 437.
    • Example 2
  • General method for synthesis of N-methyl-4-{5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl}-2-fluorobenzamide 1.2(2), N-methyl-4-{(S)-5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl}-2-fluorobenzamide (S)-1.2(2) and N-methyl-4-{(R)-5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl}-2-fluorobenzamide (R)-1.2(2).
    (D,L)-, (D)- or (L)-Alanine (347 mg, 7.8 mmol) and Cs2CO3 (2-54 g, 7.8 mmol) were added to the solution of N-methyl-2,4-difluorobenzamide (667 mg, 3.9 mmol) in DMSO (3 ml). The reaction mixture was stirred in closed vial at 90°C for 18 h. Cooled mixture was diluted with isopropanol, neutralized with HCl (1.36 ml, 15.6 mmol), filtered, evaporated in vacuo, and by HPLC method N-(4-methylcarbamoyl-3-fluorophenyl)alanine 4.2(2) (R1=CH3, R4=H, R5=CH3), (S)-N-(4-methylcarbamoyl-3-fluorophenyl)alanine (S)-4.2(2) or (R)-N-(4-methylcarbamoyl-3-fluorophenyl)alanine (R)-4.2(2) were isolated. LCMS (M+H)+ 241. 1H NMR (DMSO-d 6, 400 MHz): 12.66 (br. s, 1H), 7.62 (m, 1H), 7.45 (t, J = 8.8 Hz, 1H), 6.67 (br. d, J = 7.2 Hz, 1 H), 6.42 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1 H), 6.29 (dd, J1 = 14.8 Hz, J2 = 2.0 Hz, 1 H), 4.03 (m, 1 H), 2.73 (d, J = 4.4 Hz, 3H), 1.37 (d, J = 7.2 Hz, 3H). Solution of amine 4.2(2), (S)-4.2(2) or (R)-4.2(2) (110 mg, 0.46 mmol) and 4-isothiocyanato-2-(trifluoromethyl)-benzonitrile 3.2 (144 mg, 0.55 mmol) in DMF (2 ml) was stirred at 90°C for 12 h in microwave oven, then additional portion of 4-isothiocyanato-2-(trifluoromethyl)-benzonitrile 3.2 (50 mg, 0.19 mmol) was added and stirring was continued for another 12 h. The reaction mixture was evaporated in vacuo, and by HPLC method N-methyl-4-{5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl}-2-fluorobenzamide 1.2(2), or N-methyl-4-{(S)-5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl}-2-fluorobenzamide (S)-1.2(2) or N-methyl-4-{(R)-5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl}-2-fluorobenzamide (R)-1.2(2) were isolated, respectively. The apparent inhibition constant of androgen receptors (Ki) for these compounds are: Ki 1,2(2) = 140.2 nM, Ki (S)-1.2(2) = 106.7 nM
    Figure imgb0018
    Ki (R)-1.2(2) = 73.6 nM, respectively. LCMS (M+H)+ 451. 1H NMR (CDCl3, 400 MHz): 8.28 (t, J = 8.6 Hz, 1 H), 8.01 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 1.2 Hz, 1 H), 7.81 (dd, J1 = 8.0 Hz, J2 = 1.2 Hz, 1 H), 7.48 (dd, J1 = 12.4 Hz, J2 = 1.6 Hz, 1 H), 7.36 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1 H), 6.72 (br. m, 1 H), 4.83 (q, J = 7.2 Hz, 1 H), 3.08 (d, J = 4.8 Hz, 3H), 1.60 (d, J = 7.2 Hz, 3H).
    • Example 3
  • Synthesis of N-methyl-4-{2-thio-3-[3-(trifluoromethyl)-4-cyanophenyl]-hydantoin-1-yl}-2-fluorobenzamides 1.2.2 and 1.2.3 (general method). Solution of the corresponding N-methyl-2-fluoro-4-[(1-cyanomethyl)amino]benzamide 4.1 (0.75 mmol) and 4-isothiocyanato-2-(trifluoromethyl)benzonitrile 3.2 (342 mg, 1.5 mmol) in DMF (3 ml) was stirred at 110 °C for 12 h in microwave oven. The reaction mixture was dissolved in MeOH (30 ml), 1N HCl (7.5 ml) was added and the resultant mixture was boiled for 1.5 h. The solution was evaporated in vacuo, treated with water, the solid was filtered off, washed with water and dried in vacuo. The product was isolated by HPLC method. It gave: N-methyl-4-[5-methyl-5-(methoxymethyl)-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-imidazolidin-1-yl]-2-fluorobenzamide 1.2.2(1), Ki 1.2.2(1) = 115.9 nM, which was separated to enantiomers by means of high pressure liquid chromatography on Chiralpak HD-H 25x1 cm (Chiral Technologies Inc., USA). Mixture of 80% n-hexane, 20% 2-propanol and 0.02% triethylamine was used as eluent. Flowrate was 4 ml/min. It gave optically pure isomers (R)-1.2.2(1) and (S)-1.2.2(1), Ki (R)-1.2.2(1) = 53.3 nM, Ki (S).1.2.2(1) = 721.5 nM. LCMS (M+H)+ 495. 1H NMR (CDCl3, 400 MHz): 8.28 (t, J = 8.4 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1 H), 7.92 (s, 1 H), 7.80 (d, J = 8.0 Hz, 1 H), 7.29 (dd, J1 = 8.8 Hz, J2 = 1.2 Hz, 1 H), 7.21 (dd, J1 = 11.6 Hz, J2 = 1.2 Hz, 1 H), 6.72 (q, J = 4.4 Hz, 1 H), 3.71 (d, J = 10.0 Hz, 1 H), 3.43 (s, 3H), 3.35 (d, J = 10.0 Hz, 1 H), 3.09 (d, J = 4.4 Hz, 3H), 1.52 (s, 3H); N-methyl-4-{5-[(benzyloxy)methyl]-5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl}-2-fluorobenzamide 1.2.2(2). LCMS (M+H)+ 571. 1H NMR (CDCl3, 400 MHz): 8.22 (t, J = 8.4 Hz, 1 H), 7.96 (d, J = 8.0 Hz, 1 H), 7.86 (s, 1 H), 7.70 (dd, J1 = 8.0 Hz, J2 = 1.2 Hz, 1H), 7.39 (m, 3H), 7.29 (m, 2H), 7.25 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1 H), 7.18 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1 H), 6.71 (q, J = 4.8 Hz, 1 H), 4.59 (m, 2H), 3.79 (d, J = 10.2 Hz, 1 H), 3.45 (d, J = 10.2 Hz, 1 H), 3.08 (d, J = 4.8 Hz, 3H), 1.51 (s, 3H);
    ethyl {4-methyl-3-(4-methylcarbamoyl-3-fluorophenyl)-5-oxo-2-thioxo-1-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-4-yl}acetate 1.2.2(4) (R1=CH3, R4=CH3, R5=CH2COOC2H5). LCMS (M+H)+ 536. 1H NMR (CDCl3, 400 MHz): 8.26 (t, J = 8.4 Hz, 1H), 8.01 (d, J = 8.0 Hz, 1 H), 8.00 (s, 1 H), 7.90 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H), 7.18 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H), 7.10 (dd, J1 = 8.0 Hz, J 2 = 1.6 Hz, 1 H), 6.78 (q, J = 4.8 Hz, 1 H), 4.26 (m, 1H), 3.13 (d, J = 18.0 Hz, 1 H), 3.09 (d, J = 4.8 Hz, 3H), 2.64 (d, J = 18.0 Hz, 1 H), 1.67 (s, 3H), 1.31 (t, J = 7.0 Hz, 3H); N-methyl-4-{4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-7-oxa-1,3-diazaspiro[4.4]non-1-yl}-2-fluorobenzamide 1.2.3(1), Ki 1.23(1) = 33.9 nM. LCMS (M+H)+ 493. 1H NMR (CDCl3, 400 MHz): 8.30 (t, J = 8.4 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1 H), 7.98 (d, J = 1.6 Hz, 1 H), 7.85 (dd, J1 = 8.4 Hz, J 2 = 1.6 Hz, 1 H), 7.34 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1 H), 7.25 (dd, J1 = 11.8 Hz, J 2 = 1.6 Hz, 1 H), 6.78 (q, J = 4.4 Hz, 1H), 4.43 (d, J = 10.0 Hz, 1H), 4.16 (d, J = 10.0 Hz, 1 H), 3.96 (m, 1 H), 3.75 (m, 1 H), 3.09 (d, J = 4.4 Hz, 3H), 2.74 (m, 1 H), 2.48 (m, 1 H); N-methyl-4-{4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-8-oxa-1,3-diazaspiro[4.5]dec-1-yl}-2-fluorobenzamide 1.2.3(2). LCMS (M+H)+ 507. 1H NMR (CDCl3, 400 MHz): 8.32 (t, J = 8.4 Hz, 1 H), 8.01 (d, J = 8.0 Hz, 1H), 7.95 (s, 1 H), 7.83 (d, J = 8.0 Hz, 1 H), 7.20 (d, J = 8.4 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1 H), 6.73 (br. m, 1 H), 4.18 (m, 2H), 3.94 (m, 2H), 3.09 (d, J = 4.4 Hz, 3H), 2.07 (m, 4H); N-methyl-4-{8-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-1,3,8-triazaspiro[4.5]dec-1-yl}-2-fluorobenzamide 1.2.3(3). Ki 1.2.3(3) = 39.2 nM, IC50 =170nM. LCMS (M+H)+ 520. 1H NMR (DMSO-d 6, 400 MHz): 10.09 (br. s, 1 H), 8.48 (q, J = 4.4 Hz, 1 H), 8.43 (d, J = 8.4 Hz, 1 H), 8.29 (s, 1 H), 8.11 (d, J = 8.4 Hz, 1H), 7.84 (t, J = 8.0 Hz, 1H), 7.42 (d, J = 10.4 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1 H), 3.50 (m, 4H), 2.80 (d, J = 4.4 Hz, 3H), 2.78 (s, 3H), 2.72 (d, J = 14.0 Hz, 1 H), 2.16 (m, 2H).
    • Example 4
  • Synthesis of N-methyl-[5-(hydroxymethyl)-5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl]-2-fluorobenzamide 1.2.2(3). BBr3 (53 mkl, 0.55 mmol) was added dropwise to solution of N-methyl-4-[5-methyl-5-(methoxymethyl)-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl]-2-fluorobenzamide (55 mg, 0.11 mmol) in CH2Cl2 (1.5 ml) in argon atmosphere at -78°C. The reaction mixture was stirred at -78 °C for 3 h and then for another 3 h at room temperature. After the reaction was completed the excess of BBr3 was neutralized by addition of 5% Na2CO3 solution (10 ml), the product was extracted with AcOEt, dried over Na2SO4, evaporated in vacuo, and by HPLC method N-methyl-4-[5-(hydroxymethyl)-5-methyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-1-yl]-2-fluorobenzamide 1.2.2(3) was isolated, Ki 1.2.2(3) = 46.3 nM, 1H NMR (DMSO-d 6, 400 MHz): 8.43 (br. m, 1 H), 8.39 (d, J = 8.4 Hz, 1 H), 8.13 (s, 1 H), 7.98 (d, J = 8.4 Hz, 1 H), 7.78 (t, J = 8.0 Hz, 1 H), 7.42 (d, J = 10.8 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1N), 5.93 (t, J = 4.4 Hz, 1H), 3.81 (dd, J1 = 11.6 Hz, J2 = 4.4 Hz, 1 H), 3.45 (dd, J1 = 11.6 Hz, J2 = 5.0 Hz, 1 H), 2.79 (d, J = 4.0 Hz, 3H), 1.38 (s, 3H).
    • Example 5
  • Synthesis of {4-methyl-3-(4-methylcarbamoyl-3-fluorophenyl)-5-oxo-2-thioxo-1-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-4-yl}acetic acid 1.2.2(5) (R1=CH3, R4=CH3, R5=CH2COOH). Solution of NaOH (7 mg, 0.172 mmol) in water (0. 5 ml) was added to the solution of ester (46 mg, 0.086 mmol) 1.2.2(4) in alcohol (2 ml), and the reaction mixture was stirred for 12 h (LCMS control). The solvent was evaporated, isopropanol (2 ml) and HCl (15 mkl, 0.172 mmol) were added, filtered and evaporated again in vacuo. {4-Methyl-3-(4-methylcarbamoyl-3-fluorophenyl)-5-oxo-2-thioxo-1-[3-(trifluoromethyl)-4-cyanophenyl]imidazolidin-4-yl}acetic acid 1.2.2(5) was isolated by HPLC method. LCMS (M+H)+ 469. 1H NMR (DMSO-d 6, 400 MHz): 13.31 (br. s, 1 H), 8.44 (m, 2H), 8.10 (s, 1 H), 7.95 (d, J = 7.6 Hz, 1H), 7.81 (t, J = 8.0 Hz, 1 H), 7.25 (d, J = 10.8 Hz, 1 H), 7.19 (d, J = 8.0 Hz, 1 H), 3.16 (d, J = = 17.6 Hz, 1H), 2.79 (d, J = 3.6 Hz, 3H), 2.70 (d, J = 17.6 Hz, 1 H), 1.59 (s, 3H).
    • Example 6
  • Synthesis of 4-[3-[3-(trifluoromethyl)-4-cyanophenyl]-2-oxo-tetrahydro-pyrimidin-1(2H)-yl]-N-methyl-2-fluorobenzamide 1.3.1. K2CO3 (109 mg, 0.79 mmol) and 1,3-dibromopropane (32 mkl, 0.32 mmol) were added to a solution of 4-[4-cyano-3-(trifluoromethyl)-phenylcarbamoylamino]-N-methyl-2-fluorobenzamide (100 mg, 0.26 mmol) 2 in DMF (2 ml). Mixture was stirred at 90°C. In 18 h another portion of K2CO3 (109 mg) and 1,3-dibromopropane (32 mkl) were added and stirring was continued at the same temperature. Addition was repeated by 2 more times. After the reaction was completed the mixture was evaporated in vacuo, the residue was dissolved in chloroform, washed with water, dried over Na2SO4, the solvent was evaporated. The product was isolated by colomn chromatography on SiO2 (eluent -AcOEt). LCMS (M+H)+ 421. 1H NMR (DMSO-d 6, 400 MHz): 8.17 (br. m, 1H), 8.13 (d, J = 8.4 Hz, 1 H), 8.07 (d, J = 2.0 Hz, 1H), 7.83 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 7.62 (t, J = 8.4 Hz, 1 H), 7.38 (dd, J1 = 12.4 Hz, J2 = 2.0 Hz, 1 H), 7.29 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1 H), 3.90 (t, J = 5.8 Hz, 2H), 3.81 (t, J = 5.8 Hz, 2H), 2.77 (d, J = 4.8 Hz, 3H), 2.21 (m, 2H).
    • Example 7
  • Synthesis of N-methyl-4-{[3-(trifluoromethyl)-4-cyanophenyl]-2,4-dioxo-tetrahydropyrimidin-1(2H)-yl}benzamide 1.3.2(1), (X=O, R1=CH3). Ethyl acrylate (8 g, 80 mmol) and DBU (0.81 g, 5.4 mmol) were added to a solution of 4-amino-N-methyl-2-fluorobenzamide (9 g, 53.6 mmol) in DMSO (90 ml) and stirring was continued for 24 h at 70°C (LCMS control). The reaction mixture was subjected to lyophilization, the residue was recrystallized from aqueous alcohol. It gave ethyl N-[4-(methylcarbamoyl)-3-fluorophenyl]-β-alaninate 5. LCMS (M+H)+ 269. 1H NMR (DMSO-d 6, 400 MHz) δ 7.57 (br. s, 1 H), 7.48 (t, J = 8.8 Hz, 1 H), 6.47 (br. s, 1H), 6.42 (d, J = 8.8 Hz, 1 H), 6.33 (d, J = 14.8 Hz, 1 H), 4.07 (q, J = 7.2 Hz, 2H), 3.32 (br. m, 2H), 2.73 (d, J = 4.4 Hz, 3H), 2.55 (t, J = 6.4 Hz, 2H), 1.18 (t, J = 7.2 Hz, 3H). The solution of 4-isocyanato-2-(trifluoromethyl)benzonitrile (425 mg, 1.87 mmol) 3.1 and ethyl N-[4-(methylcarbamoyl)-3-fluorophenyl]-β-alaninate (500 mg, 1.87 mmol) 5 (R1=CH3) in CH2Cl2 (10 ml) was stirred for 5 h. The reaction mixture was evaporated in vacuo, and the product was isolated by colomn chromatography on SiO2 (eluent - n-hexane : AcOEt : Et3N = 1:1:0.03). It gave ethyl N-[4-(methylcabamoyl)-3-fluorophenyl]-N-{[3-(trifluoromethyl)-4-cyanophenyl]-carbamoyl}-β-alaninate 6(1) (R1=CH3, X=O). LCMS (M+H)+ 481. HCl (2.5 ml) was added to the solution of ethyl N-[4-(methylcabamoyl)-3-fluorophenyl]-N-{[3-(trifluoromethyl)-4-cyanophenyl]-carbamoyl}-β-alaninate (500 mg, 1.04 mmol) 6(1) in AcOH (5 ml) and the resultant mixture was stirred for 15 h. The reaction mixture was poured into water, the product was extracted with EtOAc. Organic layer was dried over Na2SO4, evaporated in vacuo and by means of colomn chromatography on SiO2 (eluent - n-hexane : AcOEt = 1:1) N-methyl-4-{[3-(trifluoromethyl)-4-cyanophenyl]-2,4-dioxo-tetrahydropyrimidin-1(2H)-yl}benzamide 1.3.2, (X=O, R1=CH3) was isolated; Ki 1.3.2(1) = 85.6 nM, LCMS (M+H)+ 435. 1H NMR (DMSO-d 6, 400 MHz): δ 8.29 (d, J = 7.6 Hz, 1H), 8.23 (br. m, 1H), 8.11 (s, 1 H), 7.89 (d, J = 2.0 Hz, 1 H), 7.67 (t, J = 8.4 Hz, 1 H), 7.39 (d, J = 12.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1 H), 4.02 (t, J = 6.4 Hz, 2H), 3.03 (t, J = 6.4 Hz, 2H), 2.77 (d, J = 4.4 Hz, 3H).
    • Example 8
  • Synthesis of N-methyl-4-{[3-(trifluoromethyl)-4-cyanophenyl]-4-oxo-2-thioxo-tetrahydropyrimidin-1(2H)-yl}benzamide 1.3.2(2), (X=S, R1=CH3). A solution of 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (320 mg, 1.51 mmol) 3.2 and ethyl N-[4-(methylcarbamoyl)-3-fluorophenyl]-β-alaninate (404 mg, 1.51 mmol) 5 (R1=CH3) in DMF (8 ml) was heated at 60°C in microwave stove for 8 h. The reaction mixture was evaporated in vacuo, and by means of colomn chromatography on SiO2 (eluent - n-hexane : AcOEt = 1:2) ethyl N-[4-(methylcarbamoyl)-3-fluorophenyl]-N-{[3-(trifluoromethyl)-4-cyanophenyl]thiocarbamoyl}-β-alaninate 6(2) (R1=CH3, X=S) was isolated. LCMS (M+H)+ 497. A solution of NaOH (32 mg, 0.8 mmol) in water (0.25 ml) was added to a solution of ester (200 mg, 0.4 mmol) 6(2) in alcohol (1 ml), and the resultant mixture was stirred at 80°C for 2 h (LCMS control), cooled and neutralized with HCl (69 mkl, 0.8 mmol), evaporated in vacuo, the residue was extracted with hot isopropanol and evaporated in vacuo again. It gave N-[4-(methylcarbamoyl)-3-fluorophenyl]-N-{[3-(trifluoromethyl)-4-cyanophenyl]thiocarbamoyl}-β-alanine 6(3) (R1=CH3, X=S). LCMS (M+H)+ 469. TBTU (86 mg, 0.36 mmol) and diisopropylethylamine (110 mg, 0.84 mmol) were added to the solution of the prepared acid (114 mg, 0.24 mmol) 6(3) in DMF (1.5 ml). The reaction mixture was stirred at 45°C for 15 h. When the reaction was completed (LCMS control) the solution was poured into water and extracted with EtOAc. The organic layer was dried over Na2SO4, evaporated in vacuo and by HPLC method N-methyl-4-{[3-(trifluoromethyl)-4-cyanophenyl]-4-oxo-2-thioxo-tetrahydropyrimidin-1(2H)-yl}-2-fluorobenzamide 1.3.2(2) (R1=CH3, X=S) was isolated; Ki 1.3.2(2) = 95.2 nM. LCMS (M+H)+ 451. 1H NMR (DMSO-d 6, 400 MHz): 8.35 (q, J = 4.4 Hz, 1 H), 8.27 (d, J = 8.0 Hz, 1 H), 8.06 (d, J = 1.6 Hz, 1 H), 7.83 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H), 7.71 (t, J = 8.2 Hz, 1 H), 7.42 (dd, J1 = 11.0 Hz, J2 = 1.8 Hz, 1 H), 7.33 (dd, J1 = 8.2 Hz, J2 = 1.8 Hz, 1 H), 4.13 (t, J = 6.8 Hz, 2H), 3.17 (t, J = 6.8 Hz, 2H), 2.78 (d, J = 4.4 Hz, 3H).
    • Example 9
  • Synthesis of N-methyl-2-fluoro-4-[4-[3-(trifluoromethyl)-4-cyanophenyl]-3,5-dioxo-1,2,4-triazolidin-1-yl]benzamide 1.4 (R1=CH3). 2.5M Solution of NaNO2 (2.38 ml) was added dropwise to a solution of 4-amino-N-methyl-2-fluorobenzamide (1 g, 5.95 mmol) in B 5N HCl (3.1 ml), so that the temperature of the reaction mixture did not exceed 5°C. The mixture was stirred for additional 30 min at the same temperature, after that the prepared solution was added drop by drop to a suspension of SnCl2*2H2O (4.03 g, 17.9 mmol) in HCl (4.2 ml) at 0°C, and stirring was continued for 2 h at the same temperature. Precipitated solid was filtered off, dissolved in water (40 ml) and NaOH was added to strongly basic reaction. The mixture was extracted with ether (3*100 ml), dried over MgSO4 and evaporated in vacuo. It gave 4-hydrazino-N-methyl-2-fluorobenzamide 7 (R1=CH3). LCMS (M+H)+ 184. 1H NMR (CDCl3, 400 MHz): 7.96 (t, J = 8.4 Hz, 1 H), 6.64 (br. m, 1 H), 6.60 (t, J = 1.6 Hz, 1 H), 6.57 (dd, J1 = 7.2 Hz, J2 = 2.0 Hz, 1 H), 5.60 (br. s, 1 H), 3.66 (br. s, 2H), 3.00 (dd, J1 = 4.8 Hz, J2 = 1.2 Hz, 1 H). The solution of 4-isocyanato-2-(trifluoromethyl)benzonitrile (59 mg, 0.27 mmol) 3.1 in dioxane (2 ml) was added to a solution of 4-hydrazino-N-methyl-2-fluorobenzamide (54 mg, 0.29 mmol) 7 in dioxane (3 ml), and the resultant mixture was stirred for 2 h. Then dioxane was distilled in vacuo, the residue was crumbled with ether, filtered off and dried in vacuo. It gave 2-[(4-methylcarbamoyl)-3-fluorophenyl]-N-[3-(trifluoromethyl)-4-cyanophenyl]-hydrazine carboxamide 8(1) (R1=CH3). LCMS (M+H)+ 405. 1H NMR (DMSO-d 6, 400 MHz): 9.65 (br. s, 1 H), 8.72 (br. s, 1 H), 8.37 (s, 1H), 8.25 (br. s, 1 H), 8.03 (br. m, 1 H), 7.88 (d, J = 8.8 Hz, 1H), 7.58 (m, 2H), 6.63 (d, J = 8.4 Hz, 1 H), 6.48 (d, J = 14.0 Hz, 1H), 2.77 (d, J = 4.4 Hz, 3H). Triethylamine (56 mkl, 0.4 mmol) and diphosgene (27 mkl, 0.22 mmol) were added one after another to 2-[(4-methylcarbamoyl)-3-fluorophenyl]-N-[3-(trifluoromethyl)-4-cyanophenyl]-hydrazine carboxamide (80 mg, 0.2 mmol) 8(1) in dichloroethane (2 ml). The reaction mixture was stirred in a closed vial at 80 °C for 15 h. The solvent was evaporated in vacuo and the residue was subjected to chromatography on SiO2 (eluent - CH2Cl2: MeOH, gradient from 100:1 till 20:1). It gave N-methyl-2-fluoro-4-[4-[3-(trifluoromethyl)-4-cyanophenyl]-3,5-dioxo-1,2,4-triazolidin-1-yl]benzamide 1.4 (R1=CH3). Ki 1.4 = 55.2 nM, LCMS (M+H)+ 422. 1H NMR (DMSO-d 6, 400 MHz): 11.53 (s, 1 H), 8.22 (br. m, 1 H), 8.16 (d, J = 8.8 Hz, 1 H), 7.99 (dd, J1 = 8.8 Hz, J2 = 1.6 Hz, 1 H), 7.95 (d, J = 1.6 Hz, 1 H), 7.81 (t, J = 8.4 Hz, 1 H), 7.69 (dd, J1 = 8.8 Hz, J2 = 2.0 Hz, 1 H), 7.62 (dd, J1 = 12.0 Hz, J2 = 2.0 Hz, 1 H), 2.79 (d, J = 4.4 Hz, 3H).
    • Example 10
  • Determination of antagonistic activity of cyclic N,N'-diarylthioureas and N,N'-diarylureas of the general formula 1 and their analog MDV3100 towards androgen receptors. The ability of novel cyclic N,N'-diarylthioureas and N,N'-diarylureas of the general formula 1 and MDV3100 agent to block androgen receptors was determined by their effectiveness of inhibition of dihydrotestosterone stimulated expression of prostate specific antigen (PSA) in cancer cells of human prostrate LNCap, derived from the American Tissue Culture Collection (ATCC, USA). These cells are sensitive towards 5-α-dihydrotestosterone (DHT) and in its presence produce cancer markers (PSA). The cells were cultured in RPMI 1640 medium (Invitrogen, USA) containing 10% calf serum (Hyclone, USA), 1% antibacterial/antifungal mixture (Sigma, USA) and 4,5% glucose. Before the experiment the cells were washed and suspended in the same medium in which, however, instead of calf serum the serum which had been treated with charcoal for removal of hormone traces was used. The cells were embedded into wells of 96-well plates by 100 µl per cell (10 000 cells) and left for 4 days in incubator at 37°C (100% humidity) in atmosphere of 95% air/5% CO2. After incubation cyclic N,N'-diarylthioureas or N,N'-diarylureas of the general formula 1 were added to the cells in various concentrations, and then - 20nM DHT (concentration corresponding to 80-90% of maximum stimulation). The cells were left for 5 days for additional incubation under the same conditions. After that the samples of supracellular medium were taken on analysis for PSA content. The test was carried out according to the protocol, recommended by manufacturer of the kit for determination of PSA (Alpha Diagnostic International, USA). After wetting the wells containing PSA antibodies attached to their bottom to each well 25 µl of the tested compounds and 100 µl of PSA antibodies conjugated previously with horseradish peroxidase were added successively.
  • After incubation at room temperature for 30 minutes, the contents of the wells were removed, the wells were washed several times, and then 100 µl of chromogenic substrate of peroxidase was added to each well. Plates were held for 15 min. at room temperature, after that 50 µl of stop solution was added to every well; at that a dye is formed the absorption intensity of which was mesured at 450 nM; the value obtained is proportional to PSA concentration in the sample. Based on the dependence of lowering of PSA synthesis, caused by dihydrotestosterone (DHT), on the concentration of the tested compounds, dose-response curves were plotted, from which IC50 values were determined. They were used for calculation of the values of apparent inhibition constants (Ki) for the compounds of the general formula I according to Cheng-Prusoff equation. [Cheng, Y., Prusoff, W. H. "Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction". Biochem Pharmacol. (1973) 22, 3099-3108]: K i = lC 50 / 1 + L / K D ,
    Figure imgb0019
     wherein L - agonist concentration (DHT), KD - receptor activation constant, numerically equal to EC50 value, which is determined in every experiment according to dependence of stimulation of PSA synthesis on DHT concentration. The data obtained given in the corresponding examples testify that novel androgen receptor antagonists, in some cases, are more active than MDV3100, tested under the same conditions as a compound for comparison, for which Ki MDV3100 = 79.5 nM.
    • Example 11
  • Determination of maximum tolerated dose of novel antagonists 1.2.2(1), and 1.2.3(3) and its analog MDV3100. Maximum tolerated dose (MTD) of novel antagonists 1.2.2(1) and 1.2.3(3) and its analog MDV3100 were determined in experiments on male mice of CD1 line at peroral administration 1 time a day within 5 days in doses 10, 30 and 100 mg/kg. The compound was dissolved in sterile water with addition of Twin-80. Sterile water with Twin-80 was introduced to control animals (Placebo group). Body weight was appreciated, and also animals' mortality rate. Statistical comparison of groups was carried out according to non-parametric test ANOVA, with the use of Statistica programme.
  • At the introduction of compounds in dose up to 100 mg/kg mice death was not observed. On the 3rd - 4th day body weight of mice in the group, received the tested compound in dose 100 mg/kg was less in comparison with the body weight of control animals, however, statistical significance at this was not observed (fig.1). The data show that compound has MTD > 100 mg/kg.
  • At the introduction of MDV3100 in doses 10 and 30 mg/kg mice death was not observed. In the group of mice to which the tested compound was introduced in dose 100 mg/kg, the body weight began to lower on the 3rd day. On the 5th day body weight of this group of animals statistically differed from body weight of animals from Placebo group (p=0,002, fig. 2). One animal died. The data show that compound MDV3100 has MTD ~ 30 mg/kg.).
    • Example 12
  • Preparation of medicament in the form of tablets. Starch (1600 mg), grained lactose (1600 mg), talcum (400 mg) and N-methyl-4-[5-methyl-5-(methoxymethyl)-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-imidazolidin-1-yl]-2-fluorobenzamide (R)-1.2.2(1) (1000 mg) mixed together and pressed in a brick. Prepared brick was crushed to granules and riddled through sieves, gathering granules of 14-16 mesh size. The obtained granules were pelletised in tablets of suitable form of 560 mg by weight each.
    • Example 13
  • Preparation of medicament in the form of capsules. N-Methyl-4-[5-methyl-5-(methoxymethyl)-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-imidazolidin-1-yl]-2-fluorobenzamide (R)-1.2.2(1) was carefully mixed with lactose powder in ratio 2 : 1. The prepared pharmaceutical composition was packed on 300 mg into gelatinous capsules of suitable size.
    • Example 16
  • Preparation of medicament in the form of compositions for intramuscular, intraperitoneal or hypodermic injections. N-Methyl-4-[5-methyl-5-(methoxymethyl)-4-oxo-2-thioxo-3-[3-(trifluoromethyl)-4-cyanophenyl]-imidazolidin-1-yl]-2-fluorobenzamide (R)-1.2.2(1) (500 mg) was dissolved in the mixture of chlorobutanole (300 mg), propylene glycol (2 ml), and water for injections (100 ml). The prepared solution was filtered and placed in 1 ml ampoules which were sealed up and sterilized in an autoclave.
    • Industrial applicability
  • The present invention could be used in medicine, veterinary, biochemistry.

Claims (12)

  1. A cyclic N,N'-diarylthioureas and N,N'-diarylurea compound of general formula 1, or optical (R)- or (S)- isomer, or a pharmaceutically acceptable salt thereof, exhibiting properties of androgen receptor antagonists,
    Figure imgb0020
     wherein:
    X represents oxygen or sulfur;
    m = 0 or 1;
    R1 represents C1-C3alkyl;
    R2 and R3 represent hydrogen; or
    R2 and R3 together with the carbon atom they are attached to form C = O group;
    R4 and R5 represent hydrogen; or
    R4 represents hydrogen, R5 represents methyl; or
    R4 represents methyl, R5 represents CH2R6 group in which R6 is C1-C3 alkoxycarbonyl, carboxyl, hydroxyl group optionally substituted with methyl or benzyl; or
    R4 and R5 together with the carbon atom they are attached to form 5- or 6-membered saturated heterocycle including at least one oxygen atom or nitrogen atom optionally substituted with methyl, or
    R4 and R5 together with the carbon atom they are attached to represent NH-group.
  2. The compound of claim 1 selected from cyclic N,N'-diarylthioureas and N,N'-diarylureas of general formulas 1.2, 1.3 or 1.4, or optical (R)- and (S)- isomers, or a pharmaceutically acceptable salt thereof,
    Figure imgb0021
     wherein:
    X, R1 , R2, R3, R4 and R5 are all as mentioned above.
  3. The compound of claim 2 selected from the group consisting of cyclic N,N'-diarylthioureas of formulas 1.2(1), 1.2(2), 1.2.2, and 1.2.3, or optical (R)-isomers - (R)-1.2(2), (R)-1.2.2, (R)-1.2.3, or (S)-isomers - (S)-1.2(2), (S)-1.2.2 and (S)-1.2.3, or a pharmaceutically acceptable salt thereof,
    Figure imgb0022
    Figure imgb0023
    Figure imgb0024
    Figure imgb0025
     wherein:
    R4 and R5 together with the carbon atom they are attached to form 5- or 6-membered saturated heterocycle comprising at least one oxygen atom or nitrogen atom optionally substituted with methyl,
    R6 has the above meanings.
  4. The compound of claim 2 selected from the group consisting of compounds of formulas 1.2.2(1), 1.2.2(2), 1.2.2(3), 1.2.3(1), 1.2.3(2) and 1.2.3(3), or optical (R)-isomers - (R)-1.2.2(1), (R)-1.2.2(2), (R)-1.2.2(3), (R)-1.2.3(1), or (S)-isomers - (S)-1.2.2(1), (S)-1.2.2(2), (S)-1.2.2(3), (S)-1.2.3(1), or a pharmaceutically acceptable salt thereof,
    Figure imgb0026
    Figure imgb0027
    Figure imgb0028
     wherein:
    R6 is hydroxyl group optionally substituted with methyl or benzyl.
  5. Method for preparation of compounds of the general formula 1.2 and their optical (R)- and (S)- isomers according to claims 1-4 by interaction of the corresponding 4-(cyanomethyl)amino-benzamides 4.1 or (4-carbamoylphenylamino)-acetic acids 4.2 or their optical (R)- and (S)-isomers with isothiocyanate 3.2.
    Figure imgb0029
  6. Anticancer agent representing at least one cyclic N,N'-diarylthiourea or N,N'-diarylurea of the general formula 1 according to any of claims 1 - 4 exhibiting properties of androgen receptor antagonists.
  7. Pharmaceutical composition exhibiting properties of androgen receptor antagonist comprising as active component anticancer agent according to claim 6.
  8. Method for preparation of pharmaceutical composition according to claim 7 by mixing anticancer agent according to claim 6 with inert filler and/or solvent.
  9. A medicament in the form of tablets, sheaths or injections for treatment of cancerous diseases comprising anticancer agent according to claim 6 or pharmaceutical composition according to claim 7.
  10. The medicament according to claim 9 intended for prostate cancer treatment.
  11. A method for treatment of cancerous diseases, among them prostate cancer, by introduction of medicament according to any of claims 9, 10, or pharmaceutical composition according to claim 7, or anticancer agent according to claim 6.
  12. Androgen receptor antagonists according to claim 1 for investigation of molecular mechanism of inhibition and activation of androgen receptors.
EP11809933.2A 2010-07-22 2011-07-01 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same Withdrawn EP2597086A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DK14001526.4T DK2767531T3 (en) 2010-07-22 2011-07-01 Cyclic n, n'-diarylthioureas and n, n'-diarylurines as androgen receptor antagonists, anti-cancer agent, method of preparation and use thereof
EP14001526.4A EP2767531B1 (en) 2010-07-22 2011-07-01 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
CY20171100307T CY1119184T1 (en) 2010-07-22 2017-03-10 CIRCULAR N, N'-DYL-DYNARLIFICATIONS AND N, N'-DYL-DYNLARS AS ANDROGEN RECEPTOR COMPONENTS, ANTI-CANCER FACTOR, METHOD FOR PRODUCTION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010130618/04A RU2434851C1 (en) 2010-07-22 2010-07-22 Cyclic n,n'-diarylthioureas or n,n'-diarylureas - antagonists of androgen receptors, anti-cancer medication, method of obtaining and application
PCT/RU2011/000476 WO2012011840A1 (en) 2010-07-22 2011-07-01 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP14001526.4A Division EP2767531B1 (en) 2010-07-22 2011-07-01 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same

Publications (2)

Publication Number Publication Date
EP2597086A1 true EP2597086A1 (en) 2013-05-29
EP2597086A4 EP2597086A4 (en) 2013-11-06

Family

ID=45318163

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14001526.4A Active EP2767531B1 (en) 2010-07-22 2011-07-01 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
EP11809933.2A Withdrawn EP2597086A4 (en) 2010-07-22 2011-07-01 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP14001526.4A Active EP2767531B1 (en) 2010-07-22 2011-07-01 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same

Country Status (21)

Country Link
US (1) US9073874B2 (en)
EP (2) EP2767531B1 (en)
JP (1) JP5897566B2 (en)
KR (1) KR101738866B1 (en)
AU (1) AU2011280297B2 (en)
CA (1) CA2806051C (en)
CY (1) CY1119184T1 (en)
DK (1) DK2767531T3 (en)
EA (1) EA020681B1 (en)
ES (1) ES2618891T3 (en)
GE (1) GEP20166450B (en)
HR (1) HRP20170450T1 (en)
HU (1) HUE031999T2 (en)
LT (1) LT2767531T (en)
PL (1) PL2767531T3 (en)
PT (1) PT2767531T (en)
RS (1) RS55876B1 (en)
RU (1) RU2434851C1 (en)
SI (1) SI2767531T1 (en)
UA (1) UA112161C2 (en)
WO (1) WO2012011840A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104844521A (en) * 2014-02-13 2015-08-19 成都伊诺达博医药科技有限公司 Novel method for compounding medicament of Enzalutamide for resisting prostate cancer
CN104844520A (en) * 2014-02-13 2015-08-19 成都伊诺达博医药科技有限公司 Novel method for compounding enzalutamide
EP2963026A4 (en) * 2013-02-27 2016-08-03 Ltd Liability Company Avionco Substituted (r)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-enecarboxylic acid (variants) and ester thereof, method for producing and using same
EP3168214A4 (en) * 2014-07-08 2018-02-14 R-Pharm Overseas Inc. Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012225038B2 (en) * 2011-03-10 2016-03-10 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
JP6262733B2 (en) 2012-09-04 2018-01-17 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Imidazoline derivatives, their production, and their application in medicine
US9365542B2 (en) 2012-10-26 2016-06-14 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor
TWI613194B (en) * 2015-06-10 2018-02-01 台灣神隆股份有限公司 A novel process for preparing enzalutamide
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
JP7494181B2 (en) 2018-12-19 2024-06-03 セルジーン コーポレイション Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith - Patents.com
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CN116322693A (en) 2020-08-13 2023-06-23 辉瑞公司 Combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2715402B1 (en) * 1994-01-05 1996-10-04 Roussel Uclaf New phenylimidazolines optionally substituted, their process and preparation intermediates, their use as medicaments and the pharmaceutical compositions containing them.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2725206B1 (en) * 1994-09-29 1996-12-06 Roussel Uclaf NOVEL HETEROCYCLE SUBSTITUTED IMIDAZOLIDINES, THEIR PROCESS AND PREPARATION INTERMEDIATES, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2579514A1 (en) * 2004-09-10 2006-03-23 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
PT2444085E (en) 2005-05-13 2015-06-11 Univ California Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
EP2439196A1 (en) * 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2012011840A1 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2963026A4 (en) * 2013-02-27 2016-08-03 Ltd Liability Company Avionco Substituted (r)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-enecarboxylic acid (variants) and ester thereof, method for producing and using same
CN104844521A (en) * 2014-02-13 2015-08-19 成都伊诺达博医药科技有限公司 Novel method for compounding medicament of Enzalutamide for resisting prostate cancer
CN104844520A (en) * 2014-02-13 2015-08-19 成都伊诺达博医药科技有限公司 Novel method for compounding enzalutamide
CN104844521B (en) * 2014-02-13 2017-08-15 成都伊诺达博医药科技有限公司 The synthetic method of the miscellaneous Shandong amine of antiprostate cancer grace
CN104844520B (en) * 2014-02-13 2017-09-05 成都伊诺达博医药科技有限公司 A kind of method for synthesizing the miscellaneous Shandong amine of grace
EP3168214A4 (en) * 2014-07-08 2018-02-14 R-Pharm Overseas Inc. Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer

Also Published As

Publication number Publication date
HRP20170450T1 (en) 2017-05-19
LT2767531T (en) 2017-04-10
PL2767531T3 (en) 2017-08-31
JP5897566B2 (en) 2016-03-30
EA020681B1 (en) 2014-12-30
CA2806051A1 (en) 2012-01-26
EP2767531A1 (en) 2014-08-20
AU2011280297B2 (en) 2013-11-21
AU2011280297A1 (en) 2013-03-07
UA112161C2 (en) 2016-08-10
EP2597086A4 (en) 2013-11-06
SI2767531T1 (en) 2017-04-26
DK2767531T3 (en) 2017-03-13
EP2767531B1 (en) 2016-12-21
US9073874B2 (en) 2015-07-07
CA2806051C (en) 2017-02-14
JP2013532657A (en) 2013-08-19
ES2618891T3 (en) 2017-06-22
RU2434851C1 (en) 2011-11-27
KR101738866B1 (en) 2017-05-23
WO2012011840A1 (en) 2012-01-26
EA201300122A1 (en) 2013-06-28
CY1119184T1 (en) 2018-02-14
US20130116269A1 (en) 2013-05-09
HUE031999T2 (en) 2017-09-28
PT2767531T (en) 2017-03-23
GEP20166450B (en) 2016-03-25
KR20130046436A (en) 2013-05-07
RS55876B1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
EP2767531B1 (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
JP2024037954A (en) RIP1 inhibitory compounds and methods for making and using the same
NZ720444A (en) Prodrugs of pyridone amides useful as modulators of sodium channels
US6696468B2 (en) (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
JP2010518026A (en) Pyridopyrimidinone compounds useful for the treatment of diseases or conditions mediated by sodium channels
JP7395730B2 (en) Heterocyclic RIP1 inhibitory compounds
US20110212078A1 (en) Synthesis and use of heterocyclic antibacterial agents
EA019098B1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
KR20090006065A (en) Tricyclic compounds
EA027533B1 (en) Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
BG64703B1 (en) Polymorphic form of 2-(r)-(1-(r)-(3,5-bis(trifuloromethyl) phenyl) ethoxy)-3-(s)-(4-fluoro)- phenyl-4-(3-(5-oxo-1h,4h-1,2,4-triazolo)methylmorpholine, method for the preperation thereof and pharmaceutical compositions containing it
TW202021964A (en) Compound for treatment of rabies and method for treatment of rabies
AU2017326297B2 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
JP6838045B2 (en) Compound
EP3481823B1 (en) 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
KR101586507B1 (en) Amide derivative and pharmaceutical composition containing the same
US9085539B2 (en) Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof
WO2018028491A1 (en) Indoleamine2,3-dioxygenase inhibitors and uses thereof in pharmacy
NZ312799A (en) (r)-5-bromo--(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-met hoxy-6-methylamino-3-pyridinecarboxamide, process for preparation thereof
EP1572672A1 (en) Benzoxazocines and their use as monoamine-reuptake inhibitors
RU2615986C1 (en) Substituted methyl(2-{4-[3-(3-methanesulfonylamino-2-fluoro-5-chloro-phenyl)-1h-pyrazol-4-yl]pyrimidin-2-ylamino}ethyl) carbamates, process for their preparation and application
EA017630B1 (en) Substituted 3-arylsulfonylpyrazolo[1,5-a]pyrimidines, serotonin 5-htreceptor antagonists, methods for the production and use thereof
OA16304A (en) Cyclic N, N'-diarylthioureas and N, N'diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same.
JPH06179685A (en) Pyrrolothiazolecarboxamide derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20131009

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 233/86 20060101ALI20131002BHEP

Ipc: C07D 239/22 20060101ALI20131002BHEP

Ipc: A61K 31/4196 20060101ALI20131002BHEP

Ipc: C07D 233/72 20060101ALI20131002BHEP

Ipc: A61K 9/48 20060101ALI20131002BHEP

Ipc: C07D 239/10 20060101AFI20131002BHEP

Ipc: A61K 31/513 20060101ALI20131002BHEP

Ipc: C07D 471/10 20060101ALI20131002BHEP

Ipc: C07D 249/12 20060101ALI20131002BHEP

Ipc: A61K 31/4166 20060101ALI20131002BHEP

Ipc: A61K 31/527 20060101ALI20131002BHEP

Ipc: A61K 9/08 20060101ALI20131002BHEP

Ipc: A61P 35/00 20060101ALI20131002BHEP

Ipc: A61K 31/4188 20060101ALI20131002BHEP

Ipc: A61K 9/20 20060101ALI20131002BHEP

Ipc: C07D 491/107 20060101ALI20131002BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140507